

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

AMARIN CORP PLC\UK  
Form 6-K  
August 19, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE  
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT  
OF 1934

Dated: August 19, 2002

Commission file number 0-21392

AMARIN CORPORATION PLC  
(Exact name of Registrant as Specified in its Charter)

ENGLAND  
(Jurisdiction of Incorporation or  
organization of Issuer)

7 Curzon Street  
London W1J 5HG, England  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files  
or will file annual reports under cover of Form 20-F or  
Form 40-F.

☒ Form 20-F

☐ Form 40-F

Indicate by check mark whether the registrant by  
furnishing the information contained in this Form is  
also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

☐ Yes

☒ No

Attachment:

Material Events

(a) Amarin Corporation plc appoints Stefan V. Ohlsson as Managing Director of  
Amarin Development AB.

This report on Form 6-K is hereby incorporated  
by reference in the registration statement on Form F-3  
(Registration Statement No. 333-12642) of Amarin  
Corporation plc and in the prospectus contained therein,  
and in the Registration Statement on Form F-3  
(Registration No. 333-13200) of Amarin Corporation plc  
and in the prospectus contained therein, and this report  
on Form 6-K shall be deemed a part of each such  
registration statement from the date on which this  
report is filed, to the extent not superseded by

## Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

documents or reports subsequently filed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By:/s/Richard A B Stewart  
Richard A B Stewart  
Chief Executive Officer

Date: August 19, 2002

Exhibits	Index to
Exhibit Item	Sequentially Numbered Page
(a) Material Event description- Amarin Corporation plc appoints Stefan V. Ohlsson as Managing Director of Amarin Development AB	4

(a)

Exhibit

## Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

### Contacts:

Rick Stewart	Stefan Ohlsson
Chief Executive Officer	Managing Director
Amarin Corporation plc	Amarin Development AB
Phone: +44 (0) 207 907 2440	Phone: +46 (0)40 53 98 01
Email: rick.stewart@amarincorp.com	Email: Stefan.ohlsson@amarindev.se

AMARIN CORPORATION PLC APPOINTS STEFAN OHLSSON MANAGING  
DIRECTOR OF AMARIN DEVELOPMENT AB

LONDON, United Kingdom, August 19, 2002 Amarin Corporation plc  
NASDAQ - AMRN) today announced the appointment of Stefan V.  
Ohlsson as Managing Director of Amarin Development AB  
effective immediately. Mr. Ohlsson will be based at Amarin  
Development AB's headquarters in Malmo, Sweden.

Mr. Ohlsson has extensive experience in the pharmaceutical  
industry, including development, marketing and project  
management. His most recent position was with AstraZeneca  
as a Global Development Director.

"Amarin Development AB is increasingly recognised as a leader  
in the field of product development. Stefan's experience and  
capabilities will accelerate the growth of Amarin Development  
and provide further focus on achieving our goals. The recently  
announced strategic technology collaborations will also benefit  
from Stefan's expertise. We very much welcome Stefan to the  
Amarin team", commented Richard Stewart, CEO of Amarin Corporation.

Amarin Corporation plc is a specialty pharmaceutical company  
focused on neurology and pain management. The Company plans to  
become a leader in these therapeutic categories by providing  
innovative products and solutions that address significant unmet  
medical needs. For press releases and other corporate information,  
visit our website at <http://www.amarincorp.com>.

Statements in this press release that are not historical facts are  
forward-looking statements that involve risks and uncertainties  
which may cause the Company's actual results in future periods to be  
materially different from any performance suggested herein. Such  
risks and uncertainties include, without limitation, risks  
associated with the inherent uncertainty of pharmaceutical research,  
product development and commercialisation, the impact of competitive  
products and patents, as well as other risks and uncertainties  
detailed from time to time in periodic reports. For more  
information, please refer to Amarin Corporation's Annual Report for  
2001 on Form 20-F and its Form 6-Ks as filed with the U.S.  
Securities and Exchange Commission. The Company assumes no  
obligation to update information on its expectations.